New drug beats standard therapy in advanced kidney cancer
Tuesday, November 15, 2016 - 15:07
in Health & Medicine
An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase II clinical trial.